December 2016 Volume 12, Issue 12
Volume 12, Issue 12 | December 2016
December 2016
In this Issue
Editor's Focus
‘21st Century Curse’ in the making?
The U.S. Congress actually passed the 21st Century Cures Act in both houses, but while there are very bright spots in the legislation, it remains uncertain if it will be a mostly good move in the endCommentary
The next big thing
We have increasing noise out there as we make more advances, and picking up the actual signals is becoming harder and harder; maybe it's time to consider slowing down a little and increasing ambiguityGuest Commentary: The Science of cell culture--Maintaining phenotypic and genotypic heterogeneity
Through periodic testing and proper cell culture management, misidentified and contaminated cell lines can be identified before publication of results or release into the scientific community, thus protecting the validity of research results and the credibility of the biomedical community as a wholeSpecial Reports
Special Report on Biotherapeutics: Is antibody listening?
Lessons from first-generation biologics inform the evolution of the nextClinical Trials
A deluge of data
Past quarter saw Boehringer Ingelheim release results for multiple trials in pulmonary, oncology areasAduro reports on mesothelioma trial
Research shows promising results on the use of CRS- 207New disease findings and old clinical trials
Study supports using amyloid inhibitors to treat Alzheimer’s diseasePS promise in cancer
Peregrine preclinical studies support a combo approach being studied in clinical trialsNovel antiepileptic for Dravet syndrome
New extended release formulation and preclinical data set stage for Phase 1b Trial to start in mid-2017Research & Development
PrOCTOR prediction
‘Moneyball’ approach may help predict new drug toxicity in humansNew research into NR
ChromaDex says nicotinamide riboside is essential to cellular energy productionTwo-pronged response
MIT advancement in immunotherapy fights cancer in miceLipid profiling steps up a notch
Multi-lipid profiling highlighted as potential new pathway for COPD biomarker developmentADI-PEG 20 can boost antitumor immune surveillance
Findings suggest that ADI-PEG 20 could potentially enhance the activity of antitumor immune therapies, including checkpoint inhibitorsDiscovery
Chemical tags on RNA silence female X chromosome
Findings could lead to new treatments of Rett syndrome and other X-linked chromosomal female diseasesGrowing interest in IP6K1
TSRI studies show the protein is a promising target for treating obesity, diabetesNew findings about cytomegalovirus
Research into CPEB1 protein may offer hope for new therapies to fight CMV infectionAs simple as ADC
Swiss-based NBE and Czech Republic’s SOTIO sign license deal for next-gen ADCs in oncologyUbiquigent launches novel compound library designed to target deubiquitylase enzymes
Ubiquigent launches first commercially available compound library, named DUBtarget-001Amyris achieves key milestone in major drug discovery collaboration
Company’s µPharm technology platform delivers initial development work in just four months for new oncology drug developmentQ&A
Q&A: Solosec’s trajectory among antibiotics
Robert Jacks, president and chief financial officer of Symbiomix, discusses briefly the company’s product Solosec (secnidazole), a next-generation 5-nitroimidazole antibioticBusiness & Government Policy
Partnering for production
Horizon announces bioproduction outlicense deal with unnamed partnerCommenting on Cures
What are some of the life-sciences players saying about 21st Century Cures?On the cutting edge
A roundup of instrumentation, software and other tools and technology newsImproving FDA metrics and ‘quality culture’
CPhI Worldwide experts propose new FDA quality metrics system and recommend critical formulation attributesDiagnostics
Making a case for Vectra
Crescendo highlights poster data at rheumatology meeting for its multi-biomarker blood testEpic uncovers prostate cancer biomarker
Liquid biopsy test matches patients to metastatic prostate cancer treatmentNSCLC stratification
Biodesix’s VeriStrat proves capable of identifying patients who will respond to EGFR-TKI therapyContract Services
Strengthening clinical research sites
INC Research unveils Catalyst Community and Catalyst Site Network at Global Site Solutions SummitMassing in Massachusetts
Neopharm joins Boston-area research cluster with the acquisition of AvericaEnvigo’s new program to aid drug R&D
Focus shifts to new and developing tech not involving the direct use of animalsPreclinical
Onxeo announces promising potential for Beleodaq
Combining agent with checkpoint inhibitors expands therapeutic possibilities for tumor treatmentCutting the fat to treat cancer
Salk Institute researchers and collaborators develop novel cancer treatment that halts fat synthesis in cells, stunting tumor growthHealing ahead with Hsp60?
A topical treatment of the protein heals wounds in diabetic mice in just three weeks
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Driving gene therapy with nonviral vectors
Learn why nonviral vectors are on the rise in gene therapy development.
Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis
Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Advancing immuno-oncology research with cellular assays
Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
